Skip to main navigation
Lineage Cell Therapeutics
  • Company
    • About Us
    • Leadership
    • Board of Directors
    • Careers
    • Contact
  • Pipeline
    • Overview
    • OpRegen® for Dry AMD
    • OPC1
    • VAC2
  • Technology
    • Lineage Platform
    • Manufacturing
  • Media
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Leadership
      • Board of Directors
      • Committee Composition
    • Analyst Coverage
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxy Information
      • 2018 AgeX and Form 10 Information Statement
      • 2019 Form 8937
    • E-mail Alerts
    • Contact IR
  • Menu

Press Releases

Investor Relations

  • Investors Overview
  • Press Releases
  • Events and Presentations
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Committee Composition
  • Analyst Coverage
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
  • Financials & Filings
    • SEC Filings
    • Annual Report and Proxy Information
    • 2018 AgeX Form 10 and Information Statement
    • 2019 Form 8937
  • E-mail Alerts
  • Contact IR

Press Releases

March 20, 2023
RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit
March 9, 2023
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 6, 2023
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.
March 2, 2023
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023
February 22, 2023
Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
February 8, 2023
Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing Loss
© Copyright - Lineage Cell Therapeutics, Inc.   |   Terms of Use & Privacy   |   contact@lineagecell.com
  • Facebook
  • Twitter
  • RSS Feed
  • Email Alerts
Scroll to top